Our findings identify the MT1‐MMP/TSP1/αvβ3 integrin/NO pathway as a possible therapeutic target for IA and colitis since blocking this axis by inhibiting MT1‐MMP activity or competing TSP1 binding to αvβ3 integrin both diminished IA and preserved collagen fiber organization. This evidence concerns the gene MMP14 and colitis.